VIDEO: Novel agents show 'significant trend' toward better responses for relapsed LBCL
In this video, Brian T. Hill, MD, PhD, discusses research that evaluated the effectiveness of chemo-immunotherapy against three novel combination therapies in the second line or later for patients with relapsed/refractory large B-cell lymphoma.
Results from the large, multicenter, real-world comparison study, presented at ASH Annual Meeting and Exposition, showed that novel agents such as loncastuximab tesirine (Zynlonta, ADC Therapeutics), tafasitamab (Monjuvi; MorphoSys, Incyte) and polatuzumab vedotin (Polivy, Genentech) showed “significant trend” toward better responses and longer durability as compared with chemo-immunotherapy, Hill, director of the lymphoid malignancies program at Cleveland Clinic, said.
"The days for sequential lines of therapy for relapsed large B-cell lymphoma should be sort of coming to an end," he said.
"We really should be incorporating the novel agents as either a part of initial therapy with polatuzumab or in subsequent lines and then trying to get some consolidation strategies, either with bispecifics or [chimeric antigen receptor] T-cell therapy," Hill continued.
Reference:
- Nastoupil L, et al. Effectiveness of chemo-immunotherapy (CIT) and novel therapies in second or later line of therapy (2L+) for patients with relapsed/refractory (R/R) aggressive large B-cell lymphoma (LBCL). Presented at: ASH Annual Meeting and Exposition, Dec. 9-12, 2023; San Diego.
Collapse
Healio Interviews
Read more about